Video
Dr. van den Brink Highlights Four Abstracts From ASH 2015
Author(s):
Marcel R.M. van den Brink, MD, PhD, provides an overview of four notable studies being presented at the 2014 American Society of Hematology (ASH) Meeting and Exposition.
Marcel R.M. van den Brink, MD, PhD, Head, Division of Hematologic Oncology, Memorial Sloan Kettering Cancer Center, provides an overview of four notable studies being presented at the 2014 American Society of Hematology (ASH) Meeting and Exposition. Van den Brink highlights the following studies:
Therapeutic Targeting of Spliceosomal Mutant Myeloid Leukemias through Modulation of Splicing Catalysis
Stanley Chun-Wei Lee, PhD
Implications of Minimal Residual Disease Negative Complete Remission (MRD-CR) and Allogeneic Stem Cell Transplant on Safety and Clinical Outcome of CD19-Targeted 19-28z CAR Modified T Cells in Adult Patients with Relapsed, Refractory B-Cell ALL
Jae H. Park, MD
Safety and Efficacy of AG-221, a Potent Inhibitor of Mutant IDH2 That Promotes Differentiation of Myeloid Cells in Patients with Advanced Hematologic Malignancies: Results of a Phase I/II Trial
Eytan M. Stein, MD
The Abundance of Certain Bacteria in the Intestinal Flora Is Associated with Relapse after Allogeneic Hematopoietic Stem Cell Transplantation
Jonathan Peled, MD, PhD
